These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 8160199)

  • 21. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
    Thrall BD; Raha GA; Springer DL; Meadows GG
    Pigment Cell Res; 1991 Dec; 4(5-6):234-9. PubMed ID: 1823927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutathione content and growth in A549 human lung carcinoma cells.
    Kang YJ; Enger MD
    Exp Cell Res; 1990 Mar; 187(1):177-9. PubMed ID: 2298258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
    Shrieve DC; Harris JW
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
    Bertsche U; Schorn H
    Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced cadmium cytotoxicity in A549 cells with reduced glutathione levels is due to neither enhanced cadmium accumulation nor reduced metallothionein synthesis.
    Kang YJ; Clapper JA; Enger MD
    Cell Biol Toxicol; 1989 Nov; 5(3):249-59. PubMed ID: 2598084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmentation of cytostatic effect of recombinant human lymphotoxin and involvement of glutathione redox cycle.
    Matsunaga K; Mashiba H
    Eur Cytokine Netw; 1992; 3(3):307-11. PubMed ID: 1498261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of glutathione synthesis of Ascaris suum by buthionine sulfoximine.
    Hussein AS; Walter RD
    Parasitol Res; 1996; 82(4):372-4. PubMed ID: 8740556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the long-term depletion of reduced glutathione in mice administered L-buthionine-S,R-sulfoximine.
    Sun JD; Ragsdale SS; Benson JM; Henderson RF
    Fundam Appl Toxicol; 1985 Oct; 5(5):913-9. PubMed ID: 2866140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
    Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of modulators of glutathione synthesis on the hepatotoxicity of 2-methylfuran.
    Ravindranath V; Boyd MR
    Biochem Pharmacol; 1991 May; 41(9):1311-8. PubMed ID: 2018563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocyte proliferation in glutathione-depleted lymphocytes: direct relationship between glutathione availability and the proliferative response.
    Hamilos DL; Zelarney P; Mascali JJ
    Immunopharmacology; 1989; 18(3):223-35. PubMed ID: 2575086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
    Palomares T; Bilbao P; del Olmo M; Castro B; Calle Y; Alonso-Varona A
    Melanoma Res; 1999 Jun; 9(3):233-42. PubMed ID: 10465578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
    Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential cytotoxicity of buthionine sulfoximine to "normal" and transformed human lung fibroblast cells.
    Wan XS; St Clair DK
    Cancer Chemother Pharmacol; 1993; 33(3):210-4. PubMed ID: 8269602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of glutathione levels on aflatoxin B1-DNA binding in livers and kidneys of male rats and hamsters pretreated with buthionine sulfoximine and dimethylmaleate.
    Gopalan-Kriczky P; Hiruma S; Lotlikar PD
    Cancer Lett; 1994 Jan; 76(1):25-30. PubMed ID: 8124663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein.
    Versantvoort CH; Broxterman HJ; Bagrij T; Scheper RJ; Twentyman PR
    Br J Cancer; 1995 Jul; 72(1):82-9. PubMed ID: 7599070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA; Greene K; Ahmad S; Vistica DT
    Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promotion of trans-platinum in vivo effects on renal heme and hemoprotein metabolism by D,L-buthionine-S,R-sulfoximine. Possible role of glutathione.
    Mayer RD; Maines MD
    Biochem Pharmacol; 1990 May; 39(10):1565-71. PubMed ID: 2337413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase.
    Messina JP; Lawrence DA
    J Immunol; 1989 Sep; 143(6):1974-81. PubMed ID: 2789253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.